Carfilzomib Market Challenges and Opportunities (2024-2034 )
Carfilzomib Market Overview: Kyprolis, also known as carfilzomib , is an anti-cancer drug that is made from the naturally occurring substance epoxomicin. Proteasomes are known to be inhibited by oximicin. Carfilzomib inhibits the chymotrypsin-like activity via binding to the 20-S proteasome. It is used as an injection together with other medications like lenalidomide or dexamethasone to treat patients with multiple myeloma, a plasma cell-affecting form of blood cancer. Despite the drug's high viability, a few side effects are reported, such as burning, severe bloating, blood in the urine, and black stool excretion. Carfilzomib can be divided into different groups according to its kind and potency. A powerful medication called carfilzomib is used to treat plasma cell-related diseases like multiple myeloma. By preventing proteasomes—cellular components necessary for protein degradation—it inhibits the growth and metastasis of cancer cells. Patients who are experiencing a recu...